Ensysce Biosciences Stock Performance
| ENSC Stock | USD 3.45 0.11 3.09% |
The firm shows a Beta (market volatility) of 1.62, which means a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Ensysce Biosciences will likely underperform. At this point, Ensysce Biosciences has a negative expected return of -1.28%. Please make sure to confirm Ensysce Biosciences' skewness, as well as the relationship between the rate of daily change and price action indicator , to decide if Ensysce Biosciences performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
Very Weak
Weak | Strong |
Over the last 90 days Ensysce Biosciences has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of weak performance in the last few months, the Stock's basic indicators remain rather sound which may send shares a bit higher in April 2025. The latest tumult may also be a sign of longer-term up-swing for the firm shareholders. ...more
Actual Historical Performance (%)
One Day Return (3.09) | Five Day Return (11.54) | Year To Date Return (58.18) | Ten Year Return (99.99) | All Time Return (99.99) |
Last Split Factor 1:15 | Last Split Date 2024-12-06 |
1 | Acquisition by Wright Richard Chester of 49975 shares of Ensysce Biosciences subject to Rule 16b-3 | 01/17/2025 |
2 | Ensysce Biosciences Announces Positive Interim Data for Breakthrough Therapy PF614-MPAR | 01/22/2025 |
3 | Acquisition by Gower Bob G of 7919026 shares of Ensysce Biosciences subject to Rule 16b-3 | 01/31/2025 |
4 | How To Trade - Stock Traders Daily | 02/12/2025 |
5 | Ensysce Biosciences Regains Compliance with Nasdaq - ACCESS Newswire | 02/20/2025 |
6 | Disposition of 8330 shares by Carrera Eric of Ensysce Biosciences subject to Rule 16b-3 | 02/28/2025 |
7 | Ensysce Biosciences CEO Dr. Lynn Kirkpatrick and Creighton Universitys Dr. Neel Pathak Discuss the Opioid Crisis and Next Generation Opioids | 03/03/2025 |
8 | Nigeria launches eNSC Lagos puts up digital fight vs malaria | 03/06/2025 |
9 | Acquisition by Martin Steven Robert of 65850 shares of Ensysce Biosciences at 3.35 subject to Rule 16b-3 | 03/07/2025 |
10 | Ensysce Biosciences Reports Fourth Quarter and Full Year 2024 Financial Results | 03/10/2025 |
11 | Ensysce Biosciences Full Year 2024 Earnings Beats Expectations | 03/12/2025 |
12 | Diamond Equity Research Releases Update Note on Ensysce Biosciences, Inc. | 03/13/2025 |
13 | Acquisition by Lynn Kirkpatrick of 263400 shares of Ensysce Biosciences at 3.19 subject to Rule 16b-3 | 03/19/2025 |
| Begin Period Cash Flow | 1.1 T |
Ensysce |
Ensysce Biosciences Relative Risk vs. Return Landscape
If you would invest 826.00 in Ensysce Biosciences on December 23, 2024 and sell it today you would lose (481.00) from holding Ensysce Biosciences or give up 58.23% of portfolio value over 90 days. Ensysce Biosciences is currently does not generate positive expected returns and assumes 5.3892% risk (volatility on return distribution) over the 90 days horizon. In different words, 48% of stocks are less volatile than Ensysce, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Ensysce Biosciences Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Ensysce Biosciences' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Ensysce Biosciences, and traders can use it to determine the average amount a Ensysce Biosciences' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.238
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | ENSC |
Estimated Market Risk
| 5.39 actual daily | 48 52% of assets are more volatile |
Expected Return
| -1.28 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.24 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Ensysce Biosciences is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Ensysce Biosciences by adding Ensysce Biosciences to a well-diversified portfolio.
Ensysce Biosciences Fundamentals Growth
Ensysce Stock prices reflect investors' perceptions of the future prospects and financial health of Ensysce Biosciences, and Ensysce Biosciences fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Ensysce Stock performance.
| Return On Equity | -5.85 | ||||
| Return On Asset | -1.01 | ||||
| Profit Margin | (1.53) % | ||||
| Operating Margin | (2.74) % | ||||
| Current Valuation | 1.62 M | ||||
| Shares Outstanding | 1.41 M | ||||
| Price To Book | 1.30 X | ||||
| Price To Sales | 0.93 X | ||||
| Gross Profit | (2.01 M) | ||||
| EBITDA | (6.73 T) | ||||
| Net Income | (7.99 T) | ||||
| Cash And Equivalents | 3.15 M | ||||
| Cash Per Share | 0.10 X | ||||
| Total Debt | 301.66 B | ||||
| Debt To Equity | 6.91 % | ||||
| Current Ratio | 0.87 X | ||||
| Book Value Per Share | 2.73 X | ||||
| Cash Flow From Operations | (7.5 T) | ||||
| Earnings Per Share | (11.45) X | ||||
| Market Capitalization | 4.85 M | ||||
| Total Asset | 5.6 M | ||||
| Retained Earnings | (129.54 T) | ||||
| Working Capital | 3.14 M | ||||
About Ensysce Biosciences Performance
By analyzing Ensysce Biosciences' fundamental ratios, stakeholders can gain valuable insights into Ensysce Biosciences' financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Ensysce Biosciences has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Ensysce Biosciences has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | (5.86) | (6.15) | |
| Return On Tangible Assets | -1.4 M | -1.4 M | |
| Return On Capital Employed | 3.05 | 2.90 | |
| Return On Assets | -1.4 M | -1.4 M | |
| Return On Equity | (2.15) | (2.05) |
Things to note about Ensysce Biosciences performance evaluation
Checking the ongoing alerts about Ensysce Biosciences for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Ensysce Biosciences help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Ensysce Biosciences generated a negative expected return over the last 90 days | |
| Ensysce Biosciences has high historical volatility and very poor performance | |
| Ensysce Biosciences has high likelihood to experience some financial distress in the next 2 years | |
| Ensysce Biosciences currently holds 301.66 B in liabilities with Debt to Equity (D/E) ratio of 6.91, indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Ensysce Biosciences has a current ratio of 0.85, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Note, when we think about Ensysce Biosciences' use of debt, we should always consider it together with its cash and equity. | |
| Net Loss for the year was (7.99 T) with loss before overhead, payroll, taxes, and interest of (2.01 M). | |
| Ensysce Biosciences currently holds about 3.15 M in cash with (7.5 T) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.1. | |
| Latest headline from MacroaxisInsider: Acquisition by Lynn Kirkpatrick of 263400 shares of Ensysce Biosciences at 3.19 subject to Rule 16b-3 |
- Analyzing Ensysce Biosciences' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Ensysce Biosciences' stock is overvalued or undervalued compared to its peers.
- Examining Ensysce Biosciences' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Ensysce Biosciences' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Ensysce Biosciences' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Ensysce Biosciences' stock. These opinions can provide insight into Ensysce Biosciences' potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Ensysce Stock analysis
When running Ensysce Biosciences' price analysis, check to measure Ensysce Biosciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Ensysce Biosciences is operating at the current time. Most of Ensysce Biosciences' value examination focuses on studying past and present price action to predict the probability of Ensysce Biosciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Ensysce Biosciences' price. Additionally, you may evaluate how the addition of Ensysce Biosciences to your portfolios can decrease your overall portfolio volatility.
| Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
| Commodity Channel Use Commodity Channel Index to analyze current equity momentum | |
| CEOs Directory Screen CEOs from public companies around the world | |
| Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
| Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
| Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges |